Mouse Anti-CMV Glycoprotein B Antibody (200µg)

Mouse anti CMV glycoprotein B antibody, clone HCMV37, recognises a neutralising epitope on CMV glycoprotein B.

This antibody has been tested on recombinant CMV glycoprotein B and shown to bind effectively to these in direct ELISA.

Human cytomegalovirus (HCMV) is a species of the Cytomegalovirus genus of viruses, which in turn is a member of the viral family known as Herpesviridae or herpesviruses. Infection with CMV is very common, with cytomegalovirus is a species of the Cytomegalovirus genus of viruses, which in turn is a member of the viral family known as Herpesviridae or herpesviruses. It is typically abbreviated as HCMV or, commonly but more ambiguously, as CMV. CMV Virus Envelope Glycoportein B (CMV-GB) can be cleaved into glycoprotein GP55. Envelope glycoprotein that plays a role in host cell entry, cell to-cell virus transmission, and fusion of infected cells. CMV-GB may be involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. Furthermore, CMV-GB can interact with host integrin ITGB1, PDGFRA and EGFR that likely serve as postattachment entry receptors. Also, CMV-GB participates in the fusion of viral and cellular membranes leading to virus entry into the host cell. Membrane fusion is mediated by the fusion machinery composed at least of gB and the heterodimer gH/gL”>estimates suggesting that 50-80% of the population in the UK have been infected at some point with CMV. Most cases of CMV infection are asymptomatic, but it can cause illness with symptoms similar to that of Flu or glandular fever.

A significant problem associated with CMV infection results from infection of a pregnant woman, who may then pass the virus on to her newborn child, leading to congenital CMV. A child with CMV infection may experience learning difficulties, and deafness.

Cytomegalovirus glycoprotein B is an important envelope protein of HCMV, acting as a receptor for entry of the virus into fibroblasts. This protein has been the target of vaccines designed to prevent HCMV infection by preventing entry into host cells. However, the HCMV pentameric complex also acts as a receptor for host-cell entry into epithelial and endothelial cells, and vaccine results using gB alone have only shown partial success.